JPH0534949B2 - - Google Patents
Info
- Publication number
- JPH0534949B2 JPH0534949B2 JP60292427A JP29242785A JPH0534949B2 JP H0534949 B2 JPH0534949 B2 JP H0534949B2 JP 60292427 A JP60292427 A JP 60292427A JP 29242785 A JP29242785 A JP 29242785A JP H0534949 B2 JPH0534949 B2 JP H0534949B2
- Authority
- JP
- Japan
- Prior art keywords
- medium
- hbsag
- serum
- cell
- surface antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 210000004027 cell Anatomy 0.000 claims description 34
- 239000002609 medium Substances 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 210000002966 serum Anatomy 0.000 claims description 11
- 230000004663 cell proliferation Effects 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 239000007640 basal medium Substances 0.000 claims description 9
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 9
- 229960003957 dexamethasone Drugs 0.000 claims description 9
- 241000700721 Hepatitis B virus Species 0.000 claims description 8
- 210000000349 chromosome Anatomy 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 230000002380 cytological effect Effects 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 230000001464 adherent effect Effects 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 238000012423 maintenance Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 239000002245 particle Substances 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 7
- 201000007270 liver cancer Diseases 0.000 description 6
- 208000014018 liver neoplasm Diseases 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 208000006454 hepatitis Diseases 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 2
- 229960002064 kanamycin sulfate Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000001738 isopycnic centrifugation Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
Landscapes
- Genetics & Genomics (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27459384 | 1984-12-28 | ||
| JP59-274593 | 1984-12-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS61268177A JPS61268177A (ja) | 1986-11-27 |
| JPH0534949B2 true JPH0534949B2 (enrdf_load_stackoverflow) | 1993-05-25 |
Family
ID=17543899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60292427A Granted JPS61268177A (ja) | 1984-12-28 | 1985-12-27 | ヒト肝癌由来の変異細胞株ｈｕＧＫ−１４ |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS61268177A (enrdf_load_stackoverflow) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2957195B2 (ja) * | 1989-05-17 | 1999-10-04 | 株式会社シノテスト | Ｂ型肝炎ウイルス抗体検出システム |
-
1985
- 1985-12-27 JP JP60292427A patent/JPS61268177A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS61268177A (ja) | 1986-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2726641B2 (ja) | 形質転換脊椎動物細胞の製造方法およびその細胞 | |
| CA1193210A (en) | Human hepatoma derived cell line, process for preparation thereof, and uses therefor | |
| CN101687029B (zh) | 一种乙型肝炎疫苗及其制备工艺 | |
| CA1240265A (en) | Lyophilized hepatitis b vaccine | |
| US4664912A (en) | Process for the large scale production of rabies vaccine | |
| US5024938A (en) | Recombinant DNA inserted with hepatitis B virus gene, mammalian cells transformed with cloned viral DNA, and production of hepatitis B virus proteins | |
| US4442205A (en) | Simian virus recombinant that directs the synthesis of hepatitis B surface antigen | |
| CA1240266A (en) | Method for purification of hbs antigen | |
| JP2000053585A (ja) | 抗原の精製方法 | |
| CN118206622A (zh) | RSV融合前F蛋白的突变体、核酸及mRNA疫苗 | |
| CN114990075B (zh) | 一株可适用于人用疫苗细胞基质培养的柯萨奇病毒a组10型疫苗株及其应用 | |
| JPH0560915B2 (enrdf_load_stackoverflow) | ||
| JPH0314840B2 (enrdf_load_stackoverflow) | ||
| WO2008044611A1 (en) | Ipv-dpt vaccine | |
| US20250082740A1 (en) | Use of cxcl14 | |
| CA2304952A1 (en) | Mannose-receptor bearing cells and antigen conjugate for immunotherapy | |
| JP2001517709A5 (enrdf_load_stackoverflow) | ||
| JPS63501121A (ja) | 酵母細胞からｂ型肝炎表面抗原を抽出するための細胞溶解法および緩衝液 | |
| EP0062574A2 (en) | Virus protein synthesis | |
| JPH0534949B2 (enrdf_load_stackoverflow) | ||
| EP2484343A1 (en) | Hepatitis b virus antigen formulation for cell stimulation followed by therapeutic immunization | |
| JPS61158798A (ja) | Ｂ型肝炎ウイルス表面抗原の製造法 | |
| EP0235113A2 (en) | Immortalization of primary cells | |
| EP0251460A2 (en) | Method for producing hepatitis B virus core antigen (HBcAg) in yeast | |
| CN1429908A (zh) | 基因重组乙肝病毒表面抗原的基因修饰序列及其产物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |